Lv11
60 积分 2024-06-17 加入
CD303 (BDCA-2) – a potential novel target for therapy in hematologic malignancies
2小时前
已完结
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study
2个月前
已完结
Evinacumab: First Approval
2个月前
已完结
Randomized Phase I Trials - One Size Fits All?
3个月前
已完结
Apolipoprotein C-III Inhibition - Killing Two Birds with One Stone?
3个月前
已完结
RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia
3个月前
已完结
RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia
3个月前
已完结
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling
4个月前
已完结
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
5个月前
已完结
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
5个月前
已完结
皖公网安备34019202002308
